MedPlus Shares Fall Over 17% After Q1 Net Profit Declines 21%

Shares of MedPlus dropped over 17% after results; company approved Rs 155 crore capex in Hyderabad amid profitability pressure.

Advertisement
Read Time: 2 mins
MedPlus Shares Fall Over 17%
Photo: Freepix

Shares of MedPlus Health Services Ltd. plunged more than 17% on Wednesday after the pharmacy retailer reported a decline in Q1FY27 profit and a sharp contraction in operating margin. The stock opened in negative 6.90% with the stock trading at 663.70 apiece and tumbled further to drop over 17%.

The company's consolidated net profit fell 21.5% year-on-year to Rs 33.2 crore in the quarter ended June, as compared to  Rs 42.3 crore in the corresponding period last year. The revenue from operations, however, rose 21.8% to Rs 1,880 crore from Rs 1,543 crore a year earlier.

Advertisement

Operating performance remained subdued, with earnings before interest, tax, depreciation and amortisation (EBITDA) increasing just 2% to Rs 133 crore from Rs 131 crore. The EBITDA margin narrowed to 7.1% from 8.5% in the year-ago quarter, indicating pressure on profitability despite strong revenue growth. The company also approved capital expenditure of Rs 155 crore in Hyderabad.

Medplus Health Q1 Cons

  • Net Profit [RD] 21.5% At Rs 33.2 crore Vs Rs 42.3 crore YoY
  • Revenue [GU] 21.8% At Rs 1,880 crore Vs Rs 1,543 crore YoY
  • EBITDA [GU] 2% At Rs 133 crore Vs Rs 131 crore YoY
  • EBITDA Margin At 7.1% Vs 8.5% YoY
  • Approves Capex Of Rs 155 crore In Hyderabad

MedPlus Health Services Ltd. Share Price Today

MedPlus Health Services Ltd. Share Price Today
Photo Credit: (Photo: NDTV Profit)

The scrip fell as much as 17.71% to Rs 653 apiece on Wednesday at 9:43 am. This compares to a 0.65% fall in the NSE Nifty 50 Index.

Advertisement

It has fallen 26.50% in the last 12 months and 17.79% year-to-date. Total traded volume so far in the day stood at 0.16 times its 30-day average. The relative strength index was at 37.76.

Out of nine analysts tracking the company, all nine maintain a 'buy' rating, according to Bloomberg data. The average 12-month consensus price target of Rs 1,168.38 implies an upside of 73.1%

Advertisement

ALSO READ: Threat Or Opportunity? How Trump's Generic Drug Tariff Plan Could Impact Indian Pharma Stocks

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.


Loading...